ADMA Biologics Inc $ADMA Shares Acquired by Campbell & CO Investment Adviser LLC

Key Points

• Campbell & CO Investment Adviser LLC raised its stake in ADMA Biologics Inc by 100.2%, now holding 89,844 shares valued at $1,783,000.
• Notable insider trading includes Director Jerrold B. Grossman selling 10,000 shares for $213,100, and Director Lawrence P. Guiheen selling 20,000 shares for $419,200, indicating decreasing positions among insiders.
• ADMA Biologics received a revised price target increase to $32.00 from Raymond James Financial, reflecting positive outlooks, while consensus ratings from analysts remain generally favorable.

Campbell & CO Investment Adviser LLC lifted its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 100.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 89,844 shares of the biotechnology company's stock after acquiring an additional 44,957 shares during the quarter. Campbell & CO Investment Adviser LLC's holdings in ADMA Biologics were worth $1,783,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ADMA. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of ADMA Biologics in the 1st quarter worth about $35,000. SVB Wealth LLC bought a new stake in shares of ADMA Biologics in the 1st quarter worth about $35,000. Smartleaf Asset Management LLC lifted its holdings in shares of ADMA Biologics by 161.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 1,493 shares during the last quarter. Tsfg LLC bought a new stake in shares of ADMA Biologics in the 1st quarter worth about $51,000. Finally, Brooklyn Investment Group lifted its holdings in shares of ADMA Biologics by 28,655.6% in the 1st quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock worth $51,000 after acquiring an additional 2,579 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Up 0.8%

NASDAQ ADMA traded up $0.13 during trading on Thursday, reaching $17.38. 2,100,631 shares of the company's stock traded hands, compared to its average volume of 3,405,186. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The firm has a market cap of $4.15 billion, a price-to-earnings ratio of 20.21 and a beta of 0.38. The company's 50 day simple moving average is $17.77 and its two-hundred day simple moving average is $18.88. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. The business had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company's revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.13 EPS. As a group, sell-side analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Insider Transactions at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 20,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the transaction, the director owned 94,830 shares of the company's stock, valued at $1,987,636.80. The trade was a 17.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director directly owned 478,194 shares in the company, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 455,621 shares of company stock valued at $9,461,633 in the last 90 days. Insiders own 3.50% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ADMA. Raymond James Financial raised their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $27.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.